LT3001 Drug:high dose
Sponsors
Shanghai Pharmaceuticals Holding Co., Ltd
Conditions
Acute Ischemic Stroke
Phase 2
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
RecruitingNCT05686642
Start: 2023-04-06End: 2026-12-12Target: 300Updated: 2026-04-30
A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke
Not yet recruitingNCT07754825
Start: 2026-09-01End: 2027-12-31Target: 300Updated: 2026-08-10